$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)

Core Viewpoint - Monteverde & Associates PC is investigating Adverum Biotechnologies, Inc. regarding its proposed sale to Eli Lilly and Company, which involves a cash payment of $3.56 per share and contingent value rights potentially worth an additional $8.91 per share [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering millions for shareholders [1]. - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]. Group 2: Transaction Details - Under the terms of the proposed transaction, Adverum shareholders will receive $3.56 in cash per share, along with a non-transferable contingent value right (CVR) that could yield up to an additional $8.91 per CVR based on the achievement of specific milestones [1].